Sanofi (SNY) Stock: Price, Forecast & Analyst Target
Sanofi (SNY) — MoonshotScore 86/100 (Exceptional band), calculated Oct 8, 2026. Price $40.20 (+1.62%), as of the Oct 7, 2026 trading session; market cap $96.5B. Expected results Oct 30, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Sanofi · SNY · NASDAQ · Healthcare · Drug Manufacturers - General
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets.
Price as of Oct 7, 2026
Key Statistics
MoonshotScore v2 · Sanofi (SNY)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a strong balance sheet and durable growth, at a dirt-cheap price, with no real weak spot. Business Quality: Elite; Financial Safety: Sound; Valuation: Cheap; Growth Durability: Growing; Momentum: Quiet.
- quarterly revenue $13.79B (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 6 of 8
- Altman Z 1.46 · Piotroski F 7
Helping: business quality, balance-sheet strength, an attractive price, durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 83 | Exceptional | |
| 84 | Exceptional | |
| 84 | Exceptional | |
| 83 | Exceptional | |
| 83 | Exceptional | |
| 83 | Exceptional |
The score moved from 83 in the stored Oct 7, 2026 snapshot to 86 in the current publication computed Oct 8, 2026 (+3); the largest pillar moves were Financial Safety +6 and Momentum +3. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $40.20 | |
| Change on the day | +1.62% | |
| 52-week range | $39.18–$52.68 | |
| Market capitalisation | $96.5B | |
| Price / earnings (trailing) | 21.76 | |
| Shares traded on the day | 2.08M | |
| Beta (volatility vs the S&P 500) | 0.3 | |
| Dividends per share (last 12 months) | $2.42 | |
| Dividend yield (last 12 months) | 6.02% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextCouncil Score · weighted blend of 2 available disciplines
Council score for Sanofi (SNY): Strongly Bullish
77/100 · ACouncil is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 8, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 8, 2026, except a card that shows its own read date.
Watch the SNY film — every key number, told as a short cinematic story
~2 min · open the film
What is Sanofi (SNY), and what does it report?
Short answer · as of
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. Sanofi (SNY) is listed on NASDAQ. Healthcare / Drug Manufacturers General SEC filing business address: 46 Avenue DE LA Grande Armee, Paris, I0, 75017. It employs 76,493 people and is led by Belén Garijo López. In Q2 FY2026 it reported revenue of $13.79B and net income of $385M. The market values it at $96.5B.
What do the latest results show for Sanofi (SNY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $13.79B. Against analyst estimates the company has EPS beat 6 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $14.06B Jul 30, 2026
- Latest report · revenue estimate
- $15.34B Jul 30, 2026
- Latest report · revenue vs estimate
- Below estimate Jul 30, 2026
- Latest report · EPS vs estimate
- Above estimate Jul 30, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 30, 2026 | $14.06B | $15.34B | $1.2100 | $1.1000 |
| Apr 23, 2026 | $12.94B | $12.68B | $1.1000 | $1.0600 |
| Jan 29, 2026 | $14.34B | $11.71B | $0.8900 | $0.8400 |
| Oct 24, 2025 | $15.43B | $11.11B | $1.7000 | $1.6000 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $13.79B | $385M | $0.16 (diluted) |
| Q1 FY2026 | $12.60B | $1.81B | $0.75 (diluted) |
| Q4 FY2025 | $13.68B | -$898M | -$0.37 (diluted) |
| Q3 FY2025 | $14.76B | $3.14B | $1.27 (diluted) |
What are the financial strengths and risks for Sanofi (SNY)?
Short answer
The MoonshotScore pillars rate business quality, balance-sheet strength, an attractive price, durable growth as strengths. The distress and quality screens read Altman Z 1.46 · Piotroski F 7. Trailing ratios: ROE 5.5% · ROA 3.1% · current ratio 0.99 · earnings yield 4.6% · free-cash-flow yield 19.2%.
What should you watch next at Sanofi (SNY)?
Short answer · as of
The next earnings report is expected on Oct 30, 2026. Current published price targets run low $49.00 · high $50.00 · consensus $49.50 · median $49.50 against a quoted price of $40.20 (as of Oct 7, 2026).
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How does Sanofi compare with its peers?
Short answer
Sanofi's score ranks tied for 5th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1188.72 Oct 7, 2026 | $1.12T | 98 5-pillar Oct 8, 2026 | |
| $59.70 Oct 7, 2026 | $122B | 92 5-pillar Oct 8, 2026 | |
| $258.45 Oct 7, 2026 | $623B | 90 5-pillar Oct 8, 2026 | |
| $47.02 Oct 7, 2026 | $94.2B | 88 5-pillar Oct 8, 2026 | |
| Sanofi (SNY) — this page | $40.20 | $96.5B | 86 |
| $413.08 Oct 7, 2026 | $223B | 86 5-pillar Oct 8, 2026 | |
| $160.12 Oct 7, 2026 | $249B | 86 5-pillar Oct 8, 2026 | |
| $143.28 Oct 7, 2026 | $272B | 84 5-pillar Oct 8, 2026 | |
| $271.36 Oct 7, 2026 | $479B | 79 5-pillar Oct 8, 2026 | |
| $142.79 Oct 7, 2026 | $353B | 75 5-pillar Oct 8, 2026 | |
| $28.00 Oct 7, 2026 | $160B | 68 5-pillar Oct 8, 2026 | |
| $222.15 Oct 7, 2026 | $32.8B | 68 5-pillar Oct 8, 2026 | |
| $7.50 Oct 7, 2026 | $6.34B | 67 5-pillar Oct 8, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $49.00 – $50.00
- Consensus target
- $49.50
- Median target
- $49.50
Consensus record · Captured .
Measured against a quoted price of $40.20 (as of Oct 7, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 7.9% Period end Jun 30, 2026
- Previous quarter · ownership
- 8.6% Prior to period end Jun 30, 2026
- Reporting holders
- 740 Period end Jun 30, 2026
- Previous quarter · holders
- 763 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Dodge & Cox | 28,088,274 |
| Morgan Stanley | 10,702,527 |
| Fisher Asset Management, LLC | 10,627,088 |
| Bank Of America Corp /De/ | 8,008,572 |
| Invesco Ltd. | 6,798,961 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Sanofi (SNY)?
SNY Healthcare Stock FAQ
Research dated 2026-09-12; the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
How do Sanofi vaccines and consumer health products change the business?
Prescription therapies remain part of the same reported enterprise as pediatric and adult vaccines, over-the-counter remedies and personal care. Demand therefore comes from treatment uptake, immunization use and consumer purchases, not only pharmaceutical launches.
What is the SNY stock price today?
The last price recorded on this page for Sanofi (SNY) is $40.20, as of the Oct 7, 2026 trading session (source: Financial Modeling Prep (FMP) quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the SNY price target?
The analyst consensus price target for Sanofi (SNY) is $49.50 (range $49.00 to $50.00, median $49.50), per FMP data captured Oct 8, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Does SNY pay a dividend?
Yes. Sanofi (SNY) shows a trailing 12-month dividend yield of 6.02%, as of Oct 7, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (56 figures)
The 56 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | 46 Avenue DE LA Grande Armee, Paris, I0, 75017 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "46, avenue de la Grande ArmEe, Paris, IF, 75017, FR". |
FMP — 45 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $40.20 | FMP | Financial Modeling Prep (FMP) quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. | |
px.change | Change on the day | +1.62% | FMP | Financial Modeling Prep (FMP) quote | |
px.mcap | Market capitalization | $96.5B | FMP | Financial Modeling Prep (FMP) quote — Provider market cap uses the share class it prices; a company with more than one class may show a larger total elsewhere. Market cap record date: 2026-10-07. Source capture time was not supplied. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Oct 30, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
id.business_summary | Business description (FMP excerpt) | Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | +$0.64 | FMP | Financial Modeling Prep (FMP) quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $13.79B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $39.18–$52.68 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 21.76 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 2.08M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.3 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Drug Manufacturers General | FMP | Financial Modeling Prep (FMP) company profile — The company's SEC filings classify it under SIC 2834 — Pharmaceutical Preparations. | |
id.employees | Employees | 76,493 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
id.ceo | Chief executive | Belén Garijo López | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_income | Net income, Q2 FY2026 | $385M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-07-30.revenue_actual | Revenue · reported — report date 2026-07-30 | $14.06B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-30.revenue_estimated | Revenue · estimate — report date 2026-07-30 | $15.34B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-30.eps_actual | EPS · reported — report date 2026-07-30 | $1.2100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-30.eps_estimated | EPS · estimate — report date 2026-07-30 | $1.1000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-23.revenue_actual | Revenue · reported — report date 2026-04-23 | $12.94B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-23.revenue_estimated | Revenue · estimate — report date 2026-04-23 | $12.68B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-23.eps_actual | EPS · reported — report date 2026-04-23 | $1.1000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-23.eps_estimated | EPS · estimate — report date 2026-04-23 | $1.0600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-29.revenue_actual | Revenue · reported — report date 2026-01-29 | $14.34B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-29.revenue_estimated | Revenue · estimate — report date 2026-01-29 | $11.71B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-29.eps_actual | EPS · reported — report date 2026-01-29 | $0.8900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-29.eps_estimated | EPS · estimate — report date 2026-01-29 | $0.8400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-24.revenue_actual | Revenue · reported — report date 2025-10-24 | $15.43B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-24.revenue_estimated | Revenue · estimate — report date 2025-10-24 | $11.11B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-24.eps_actual | EPS · reported — report date 2025-10-24 | $1.7000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-10-24.eps_estimated | EPS · estimate — report date 2025-10-24 | $1.6000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
earn.pt | Stored analyst price targets | low $49.00 · high $50.00 · consensus $49.50 · median $49.50 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 8, 2026 · Coverage not supplied | |
earn.pt_range | Analyst price target, low to high | $49.00 – $50.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 8, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $49.50 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 8, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $49.50 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 8, 2026 · Coverage not supplied | |
own.institutions.depth.ownership_pct | Institutional ownership | 7.9% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 8.6% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 740 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 763 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Dodge & Cox — shares in provider snapshot | 28,088,274 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Morgan Stanley — shares in provider snapshot | 10,702,527 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Fisher Asset Management, LLC — shares in provider snapshot | 10,627,088 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Bank Of America Corp /De/ — shares in provider snapshot | 8,008,572 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Invesco Ltd. — shares in provider snapshot | 6,798,961 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 6 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-07 | |
fin.scores | Distress and quality screens | Altman Z 1.46 · Piotroski F 7 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-08 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 5.5% · ROA 3.1% · current ratio 0.99 · earnings yield 4.6% · free-cash-flow yield 19.2% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 4 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $2.42 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 1 split-adjusted declared dividend with an ex-date in the 365 days to 2026-10-08, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 6.02% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-07-30.revenue_actual.comparison | Latest report · revenue vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($14.06B) with the recorded estimate ($15.34B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-07-30.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($1.2100) with the recorded estimate ($1.1000) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 3 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 86 of 100 · Exceptional · pillars 88 / 71 / 91 / 70 / 57 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 83 (stored snapshot Oct 7, 2026) → 86 (current publication computed Oct 8, 2026) (+3) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. | |
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-07-30. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-07-30.revenue_actual,earn.history.depth.2026-07-30.revenue_estimated,earn.history.depth.2026-07-30.revenue_actual.comparison,earn.history.depth.2026-07-30.eps_actual.comparison,earn.history.depth.2026-07-30.eps_actual,earn.history.depth.2026-07-30.eps_estimated,earn.history.depth.2026-04-23.revenue_actual,earn.history.depth.2026-04-23.revenue_estimated,earn.history.depth.2026-04-23.eps_actual,earn.history.depth.2026-04-23.eps_estimated,earn.history.depth.2026-01-29.revenue_actual,earn.history.depth.2026-01-29.revenue_estimated,earn.history.depth.2026-01-29.eps_actual,earn.history.depth.2026-01-29.eps_estimated,earn.history.depth.2025-10-24.revenue_actual,earn.history.depth.2025-10-24.revenue_estimated,earn.history.depth.2025-10-24.eps_actual,earn.history.depth.2025-10-24.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Sector / industry (provider taxonomy) | Healthcare / Drug Manufacturers - General The company's SEC filings classify it under SIC 2834 — Pharmaceutical Preparations. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
Data provided for informational purposes only.